1 Nov 2023
Choroidal features in non-neovascular and neovascular pachychoroid diseasesPublisher siteEuropean Journal of Ophthalmology, Retinal Diseases and Treatments
Active, last published 2026
In retinal diseases and treatments
Inés
Hachicha
Scholar“Research focused on Retinal Diseases and Treatments and adjacent fields.”
University of Tunis El Manar
Tunisia
Claim Your ProfileTunisia1
H-index
2
Citations
Inés has not officially claimed their profile. If you are Inés, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
nés Hachicha is a researcher working on Retinal Diseases and Treatments. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Inés's work has been cited 2 times across 1 active year. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Retinal Diseases and Treatments×6Glaucoma and retinal disorders×5Retinal and Macular Surgery×3Retinal and Optic Conditions×3Retinal Development and Disorders×2
04 · Where I am
Affiliations
Affiliation on published researchTunis University, TunisiaDrawn from the institution listed on this researcher’s published work.
05 · Selected work
Recent publications
2 works6 Oct 20231cites
Atypical presentation of bilateral iridoschisis with abnormal visibility of iris vessels: Role of anterior segment optical coherence tomographyPublisher siteEuropean Journal of Ophthalmology, Intraocular Surgery and Lenses
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Inés?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you